PhD, Technical University Braunschweig (Germany), 12/1994
M.Sc. (Pharmacy), University of Hamburg (Germany), 04/1988
Prof. in Pharmaceutical Design and Drug Delivery, Copenhagen University, 03/2012 –
Prof. in Pharmaceutical Sciences, School of Pharmacy, University of Otago, Dunedin, New Zealand, 10/2003 – 02/2012
Senior Lecturer in Pharmaceutical Sciences, School of Pharmacy, University of Otago, Dunedin, New Zealand, 8/1999 - 9/2003
Research Scientist, Pharmaceutical Research: Preclinical Development and Formulation, F. Hoffmann-La Roche, Basel, Switzerland, 4/1998 – 7/1999
Honorary Doctorate, Åbo Akademi University, Turku, Finland 2014
Eminent Fellow of the Academy of Pharmaceutical Sciences, UK, 2013
Appointed as Honorary Professor at the School of Pharmacy, University of Otago, New Zealand, 2013-date
Appointed as Guest Professor at the Faculty of Pharmaceutical Sciences, Copenhagen University, Copenhagen, DK, 2009-2012
Otago University PhD supervisor of the year (finalist), Dunedin, NZ, 2008, 2009
Inaugural Pfizer Lecturer in Pharmaceutical Technology, University of Connecticut, USA, 2007
Fellow of the New Zealand Institute of Chemistry, 2007
New Zealand Tertiary Teaching Excellence Award, 2005
Appointed as Visiting Professor at the Department of Medicine at the University of Adelaide, Australia, 2004-date
Examples: Leo Foundation: LEO Foundation Center for Cutaneous Drug Delivery (LFCCDD): 40 mio DKK, 2017-2027; Role: PI for Formulation (15 mio DKK).
IMI EU consortium: Biopharmaceutical Tools for Oral Drug Delivery (OrBiTo) (10 big Pharma companies, 10 European universities and 2 SMEs). €10.6 mio, 2012-2017; Role: Task Leader (€0.75 mio).
Villum Kann Rasmussen Centre of Excellence “NanoMechanical Sensors” (Namec) in collaboration with DTU Nanotech. 28 mio DKK, 2009-14; Role: Task Leader (6 mio DKK).
A short summary of research interests
My whole research career, both in academia and industry (see employment record) has always focussed on improving drug delivery systems. The exact topics of course have shifted over the years, and span from colloidal delivery systems (including liposomal and other liquid crystalline systems, polymeric and lipid nanoparticles for drug and vaccine delivery) to solids state dosage forms, including polymorphic drugs and amorphous drugs delivery systems. The work is strongly based on a physicochemical underpinning of these enabling formulations, as well as a deep and thorough analytical characterisation and understanding of such systems. Work in recent years has increasingly used thermal analytical, diffractometric, and spectroscopic methods, both quantitatively and structurally. An additional focus has always been the preparative aspects of such enabling formulations, including technologies such as spray drying, melt extrusion, mechano-chemical activation, tabletting, encapsulation etc.
Details about publications: https://scholar.google.com/citations?user=jangS5sAAAAJ&hl=en
Prof. Dr. Dr. h.c.